Tackling obesity: new therapeutic agents for assisted weight loss

References

• WHO website http://www.who.int/mediacentre/factsheets/fs311/en/
   Google Scholar
• Flegal KM Carroll MD Ogden CL Johnson CL Prevalence and trends in obesity among US adults, 1999–2000 JAMA 2002 288 14 1723 1727 12365955
   PubMed Web of Science ®Google Scholar
• Ogden CL Carroll MD Curtin LR McDowell MA Tabak CJ Flegal KM Prevalence of overweight and obesity in the United States, 1999–2004 JAMA 2006 295 13 1549 1555 16595758
   PubMed Web of Science ®Google Scholar
• Sturm R Increases in clinically severe obesity in the United States, 1986–2000 Arch Intern Med 2003 163 18 2146 2148 14557211
   PubMedGoogle Scholar
• Hubert HB The importance of obesity in the development of coronary risk factors and disease: the epidemiologic evidence Annu Rev Public Health 1986 7 493 502 3718653
   PubMed Web of Science ®Google Scholar
• Adams KF Schatzkin A Harris TB Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old N Engl J Med 2006 355 8 763 778 16926275
   PubMed Web of Science ®Google Scholar
• Thompson D Edelsberg J Colditz GA Bird AP Oster G Lifetime health and economic consequences of obesity Arch Intern Med 1999 159 18 2177 2183 10527295
   PubMed Web of Science ®Google Scholar
• Wolf AM Colditz GA The cost of obesity: the US perspective Pharmacoeconomics 1994 5 Suppl 1 34 37 10147247
   PubMed Web of Science ®Google Scholar
• Bouchard C Perusse L Genetics of obesity Annu Rev Nutr 1993 13 337 354 8369150
   PubMed Web of Science ®Google Scholar
• Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults – The Evidence Report National Institutes of Health Obes Res 9 1998/11/14 51S 209S http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9813653 6 Suppl 2
   PubMedGoogle Scholar
• Lee A Morley JE Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes Obes Res 1998 6 1 47 53 9526970
   PubMedGoogle Scholar
• Karam J McFarlane S Secondary causes of obesity Therapy 2007 4 5 641 650
   Google Scholar
• Snow V Barry P Fitterman N Qaseem A Weiss K Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians Ann Intern Med 2005 142 7 525 531 15809464
   PubMed Web of Science ®Google Scholar
• National Institutes of Health, National Heart, Lung, and Blood Institute The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults NIH publication number 02-4084 2002
   Google Scholar
• UKPDS Task Force website www.ahrq.gov/clinic/USpstf/uspsobes.htm
   Google Scholar
• Knowler WC Barrett-Connor E Fowler SE Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 2002 346 6 393 403 11832527
   PubMed Web of Science ®Google Scholar
• Goldstein DJ Beneficial health effects of modest weight loss Int J Obes Relat Metab Disord 1992 16 6 397 415 1322866
   PubMed Web of Science ®Google Scholar
• Pasanisi F Contaldo F de Simone G Mancini M Benefits of sustained moderate weight loss in obesity Nutr Metab Cardiovasc Dis 2001 11 6 401 406 12055705
   PubMed Web of Science ®Google Scholar
• Heilbronn LK de Jonge L Frisard MI Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial JAMA 2006 295 13 1539 1548 16595757
   PubMed Web of Science ®Google Scholar
• Metz JA Stern JS Kris-Etherton P A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction Arch Intern Med 2000 160 14 2150 2158 10904458
   PubMedGoogle Scholar
• Arora SK McFarlane SI The case for low carbohydrate diets in diabetes management Nutr Metab (Lond) 2005 2 16 16018812
   PubMed Web of Science ®Google Scholar
• Dansinger ML Gleason JA Griffith JL Selker HP Schaefer EJ Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial JAMA 2005 293 1 43 53 15632335
   PubMed Web of Science ®Google Scholar
• Gardner CD Kiazand A Alhassan S Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial JAMA 2007 297 9 969 977 17341711
   PubMed Web of Science ®Google Scholar
• Garrow JS Summerbell CD Meta-analysis: effect of exercise, with or without dieting, on the body composition of overweight subjects Eur J Clin Nutr 1995 49 1 1 10 7713045
   PubMed Web of Science ®Google Scholar
• Jakicic JM Marcus BH Gallagher KI Napolitano M Lang W Effect of exercise duration and intensity on weight loss in overweight, sedentary women: a randomized trial JAMA 2003 290 10 1323 1330 12966123
   PubMed Web of Science ®Google Scholar
• Mathus-Vliegen EM Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study Eur J Clin Nutr 2005 59 Suppl 1 S31 38 discussion S39 16052193
   PubMed Web of Science ®Google Scholar
• Miller WC Koceja DM Hamilton EJ A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention Int J Obes Relat Metab Disord 1997 21 10 941 947 9347414
   PubMed Web of Science ®Google Scholar
• Gilliat-Wimberly M Manore MM Woolf K Swan PD Carroll SS Effects of habitual physical activity on the resting metabolic rates and body compositions of women aged 35 to 50 years J Am Diet Assoc 2001 101 10 1181 1188 11678489
   PubMedGoogle Scholar
• Chambliss HO Exercise duration and intensity in a weight-loss program Clin J Sport Med 2005 15 2 113 115 15782062
   PubMedGoogle Scholar
• Jakicic JM Winters C Lang W Wing RR Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women: a randomized trial JAMA 1999 282 16 1554 1560 10546695
   PubMed Web of Science ®Google Scholar
• Lin XM Li B Du YH Xiong J Sun P Systematic evaluation of therapeutic effect of acupuncture for treatment of simple obesity Zhongguo Zhen Jiu 2009 29 10 856 860 19873927
   PubMedGoogle Scholar
• Cho SH Lee JS Thabane L Lee J Acupuncture for obesity: a systematic review and meta-analysis Int J Obes (Lond) 2009 33 2 183 196 19139756
   PubMed Web of Science ®Google Scholar
• Hsu CH Wang CJ Hwang KC Lee TY Chou P Chang HH The effect of auricular acupuncture in obese women: a randomized controlled trial J Womens Health (Larchmt) 2009 18 6 813 818 19445642
   PubMed Web of Science ®Google Scholar
• Zhi J Melia AT Guerciolini R Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers Clin Pharmacol Ther 1994 56 1 82 85 8033498
   PubMed Web of Science ®Google Scholar
• Carriere F Renou C Ransac S Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers Am J Physiol Gastrointest Liver Physiol 2001 281 1 G16 G28 11408251
   PubMed Web of Science ®Google Scholar
• Padwal R Li SK Lau DC Long-term pharmacotherapy for obesity and overweight Cochrane Database Syst Rev 2004 3 CD004094 15266516
   PubMed Web of Science ®Google Scholar
• Ullrich A Erdmann J Margraf J Schusdziarra V Impact of carbohydrate and fat intake on weight-reducing efficacy of orlistat Aliment Pharmacol Ther 2003 17 8 1007 1013 12694082
   PubMed Web of Science ®Google Scholar
• Torgerson JS Hauptman J Boldrin MN Sjostrom L XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients Diabetes Care 2004 27 1 155 161 14693982
   PubMed Web of Science ®Google Scholar
• Li Z Maglione M Tu W Meta-analysis: pharmacologic treatment of obesity Ann Intern Med 2005 142 7 532 546 15809465
   PubMed Web of Science ®Google Scholar
• Sjostrom L Rissanen A Andersen T Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group Lancet 1998 352 9123 167 172 9683204
   PubMed Web of Science ®Google Scholar
• Chanoine JP Hampl S Jensen C Boldrin M Hauptman J Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial JAMA 2005 293 23 2873 2883 15956632
   PubMed Web of Science ®Google Scholar
• Hill JO Hauptman J Anderson JW Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study Am J Clin Nutr 1999 69 6 1108 1116 10357727
   PubMed Web of Science ®Google Scholar
• Hutton B Fergusson D Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials Am J Clin Nutr 2004 80 6 1461 1468 15585756
   PubMed Web of Science ®Google Scholar
• Tonstad S Pometta D Erkelens DW The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia Eur J Clin Pharmacol 1994 46 5 405 410 7957533
   PubMed Web of Science ®Google Scholar
• Lindgarde F The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study J Intern Med 2000 248 3 245 254 10971792
   PubMed Web of Science ®Google Scholar
• Davidson MH Hauptman J DiGirolamo M Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial JAMA 1999 281 3 235 242 9918478
   PubMed Web of Science ®Google Scholar
• Hauptman J Lucas C Boldrin MN Collins H Segal KR Orlistat in the long-term treatment of obesity in primary care settings Arch Fam Med 2000 9 2 160 167 10693734
   PubMedGoogle Scholar
• Kelley DE Bray GA Pi-Sunyer FX Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial Diabetes Care 2002 25 6 1033 1041 12032111
   PubMed Web of Science ®Google Scholar
• Hollander PA Elbein SC Hirsch IB Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study Diabetes Care 1998 21 8 1288 1294 9702435
   PubMed Web of Science ®Google Scholar
• Cavaliere H Floriano I Medeiros-Neto G Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid) Int J Obes Relat Metab Disord 2001 25 7 1095 1099 11443512
   PubMed Web of Science ®Google Scholar
• FDA website www.fda.gov/Drugs/DrugsSafety/PostMarketDrugsSafety
   Google Scholar
• Barkeling B Elfhag K Rooth P Rossner S Short-term effects of sibutramine (Reductil) on appetite and eating behaviour and the long-term therapeutic outcome Int J Obes Relat Metab Disord 2003 27 6 693 700 12833113
   PubMed Web of Science ®Google Scholar
• Hansen DL Toubro S Stock MJ Macdonald IA Astrup A Thermogenic effects of sibutramine in humans Am J Clin Nutr 1998 68 6 1180 1186 9846844
   PubMed Web of Science ®Google Scholar
• Smith IG Goulder MA Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity J Fam Pract 2001 50 6 505 512 11407998
   PubMed Web of Science ®Google Scholar
• Wirth A Krause J Long-term weight loss with sibutramine: a randomized controlled trial JAMA 2001 286 11 1331 1339 11560538
   PubMed Web of Science ®Google Scholar
• Apfelbaum M Vague P Ziegler O Hanotin C Thomas F Leutenegger E Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine Am J Med 1999 106 2 179 184 10230747
   PubMed Web of Science ®Google Scholar
• Bray GA Blackburn GL Ferguson JM Sibutramine produces dose-related weight loss Obes Res 1999 7 2 189 198 10102256
   PubMedGoogle Scholar
• James WP Astrup A Finer N Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance Lancet 2000 356 9248 2119 2125 11191537
   PubMed Web of Science ®Google Scholar
• Wadden TA Berkowitz RI Womble LG Randomized trial of lifestyle modification and pharmacotherapy for obesity N Engl J Med 2005 353 20 2111 2120 16291981
   PubMed Web of Science ®Google Scholar
• McNulty SJ Ur E Williams G A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin Diabetes Care 2003 26 1 125 131 12502668
   PubMed Web of Science ®Google Scholar
• Vettor R Serra R Fabris R Pagano C Federspil G Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies Diabetes Care 2005 28 4 942 949 15793204
   PubMed Web of Science ®Google Scholar
• Norris SL Zhang X Avenell A Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis Arch Intern Med 2004 164 13 1395 1404 15249348
   PubMedGoogle Scholar
• Arterburn DE Crane PK Veenstra DL The efficacy and safety of sibutramine for weight loss: a systematic review Arch Intern Med 2004 164 9 994 1003 15136309
   PubMedGoogle Scholar
• Sramek JJ Leibowitz MT Weinstein SP Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial J Hum Hypertens 2002 16 1 13 19 11840225
   PubMed Web of Science ®Google Scholar
• Kim SH Lee YM Jee SH Nam CM Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials Obes Res 2003 11 9 1116 1123 12972682
   PubMedGoogle Scholar
• McMahon FG Fujioka K Singh BN Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial Arch Intern Med 2000 160 14 2185 2191 10904462
   PubMed Web of Science ®Google Scholar
• McMahon FG Weinstein SP Rowe E Ernst KR Johnson F Fujioka K Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors J Hum Hypertens 2002 16 1 5 11 11840224
   PubMed Web of Science ®Google Scholar
• Scholze J Grimm E Herrmann D Unger T Kintscher U Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study Circulation 2007 115 15 1991 1998 17404163
   PubMed Web of Science ®Google Scholar
• Berkowitz RI Fujioka K Daniels SR Effects of sibutramine treatment in obese adolescents: a randomized trial Ann Intern Med 2006 145 2 81 90 16847290
   PubMed Web of Science ®Google Scholar
• Godoy-Matos A Carraro L Vieira A Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study J Clin Endocrinol Metab 2005 90 3 1460 1465 15613431
   PubMed Web of Science ®Google Scholar
• Bach DS Rissanen AM Mendel CM Absence of cardiac valve dysfunction in obese patients treated with sibutramine Obes Res 1999 7 4 363 369 10440592
   PubMedGoogle Scholar
• Zannad F Gille B Grentzinger A Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction Am Heart J 2002 144 3 508 515 12228789
   PubMed Web of Science ®Google Scholar
• Wadden TA Berkowitz RI Womble LG Sarwer DB Arnold ME Steinberg CM Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial Obes Res 2000 8 6 431 437 11011909
   PubMedGoogle Scholar
• Aydin N Topsever P Kaya A Karasakal M Duman C Dagar A Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? Tohoku J Exp Med 2004 202 3 173 180 15065643
   PubMed Web of Science ®Google Scholar
• Gokcel A Gumurdulu Y Karakose H Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity Diabetes Obes Metab 2002 4 1 49 55 11874442
   PubMed Web of Science ®Google Scholar
• Sari R Balci MK Cakir M Altunbas H Karayalcin U Comparison of efficacy of sibutramine or orlistat versus their combination in obese women Endocr Res 2004 30 2 159 167 15473126
   PubMed Web of Science ®Google Scholar
• Cota D Marsicano G Tschop M The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis J Clin Invest 2003 112 3 423 431 12897210
   PubMed Web of Science ®Google Scholar
• Van Gaal LF Rissanen AM Scheen AJ Ziegler O Rossner S Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 2005 365 9468 1389 1397 15836887
   PubMed Web of Science ®Google Scholar
• Despres JP Golay A Sjostrom L Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia N Engl J Med 2005 353 20 2121 2134 16291982
   PubMed Web of Science ®Google Scholar
• Scheen AJ Finer N Hollander P Jensen MD Van Gaal LF Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study Lancet 2006 368 9548 1660 1672 17098084
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX Aronne LJ Heshmati HM Devin J Rosenstock J Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial JAMA 2006 295 7 761 775 16478899
   PubMed Web of Science ®Google Scholar
• Curioni C Andre C Rimonabant for overweight or obesity Cochrane Database Syst Rev 2006 4 CD006162 17054276
   PubMed Web of Science ®Google Scholar
• Rosenstock J Hollander P Chevalier S Iranmanesh A SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes Diabetes Care 2008 31 11 2169 2176 18678611
   PubMed Web of Science ®Google Scholar
• Nissen SE Nicholls SJ Wolski K Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial JAMA 2008 299 13 1547 1560 18387931
   PubMed Web of Science ®Google Scholar
• Christensen R Kristensen PK Bartels EM Bliddal H Astrup A Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 2007 370 9600 1706 1713 18022033
   PubMed Web of Science ®Google Scholar
• Kernan WN Viscoli CM Brass LM Phenylpropanolamine and the risk of hemorrhagic stroke N Engl J Med 2000 343 25 1826 1832 11117973
   PubMed Web of Science ®Google Scholar
• Weissman NJ Tighe JFJr Gottdiener JS Gwynne JT An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group N Engl J Med 1998 339 11 725 732 9731088
   PubMed Web of Science ®Google Scholar
• Choi HK Atkinson K Karlson EW Curhan G Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study Arch Intern Med 2005 165 7 742 748 15824292
   PubMed Web of Science ®Google Scholar
• Haddock CK Poston WS Dill PL Foreyt JP Ericsson M Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials Int J Obes Relat Metab Disord 2002 26 2 262 273 11850760
   PubMed Web of Science ®Google Scholar
• Munro JF MacCuish AC Wilson EM Duncan LJ Comparison of continuous and intermittent anorectic therapy in obesity Br Med J 1968 1 5588 352 354 15508204
   PubMed Web of Science ®Google Scholar
• Goldstein DJ Rampey AHJr Enas GG Potvin JH Fludzinski LA Levine LR Fluoxetine: a randomized clinical trial in the treatment of obesity Int J Obes Relat Metab Disord 1994 18 3 129 135 8186809
   PubMed Web of Science ®Google Scholar
• Goldstein DJ Rampey AHJr Roback PJ Efficacy and safety of long-term fluoxetine treatment of obesity – maximizing success Obes Res 1995 3 Suppl 4 481S 490S 8697047
   PubMedGoogle Scholar
• Wadden TA Bartlett SJ Foster GD Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial Obes Res 1995 3 6 549 557 8653531
   PubMedGoogle Scholar
• Anderson JW Greenway FL Fujioka K Gadde KM McKenney J O’Neil PM Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial Obes Res 2002 10 7 633 641 12105285
   PubMedGoogle Scholar
• Shapira NA Goldsmith TD McElroy SL Treatment of binge-eating disorder with topiramate: a clinical case series J Clin Psychiatry 2000 61 5 368 372 10847312
   PubMed Web of Science ®Google Scholar
• McElroy SL Arnold LM Shapira NA Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial Am J Psychiatry 2003 160 2 255 261 12562571
   PubMed Web of Science ®Google Scholar
• Gadde KM Franciscy DM Wagner HR2nd Krishnan KR Zonisamide for weight loss in obese adults: a randomized controlled trial JAMA 2003 289 14 1820 1825 12684361
   PubMed Web of Science ®Google Scholar
• Fontbonne A Charles MA Juhan-Vague I The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group Diabetes Care 1996 19 9 920 926 8875083
   PubMed Web of Science ®Google Scholar
• Pasquali R Gambineri A Biscotti D Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome J Clin Endocrinol Metab 2000 85 8 2767 2774 10946879
   PubMed Web of Science ®Google Scholar
• Poon T Nelson P Shen L Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study Diabetes Technol Ther 2005 7 3 467 477 15929678
   PubMedGoogle Scholar
• DeFronzo RA Ratner RE Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005 28 5 1092 1100 15855572
   PubMed Web of Science ®Google Scholar
• Kendall DM Riddle MC Rosenstock J Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 2005 28 5 1083 1091 15855571
   PubMed Web of Science ®Google Scholar
• Buse JB Henry RR Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 2004 27 11 2628 2635 15504997
   PubMed Web of Science ®Google Scholar
• Blonde L Klein EJ Han J Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes Diabetes Obes Metab 2006 8 4 436 447 16776751
   PubMed Web of Science ®Google Scholar
• Ratner RE Maggs D Nielsen LL Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus Diabetes Obes Metab 2006 8 4 419 428 16776749
   PubMed Web of Science ®Google Scholar
• Hollander P Maggs DG Ruggles JA Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients Obes Res 2004 12 4 661 668 15090634
   PubMedGoogle Scholar
• Ratner RE Dickey R Fineman M Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial Diabet Med 2004 21 11 1204 1212 15498087
   PubMed Web of Science ®Google Scholar
• Vivus website www.vivus.com
   Google Scholar
• Orexigen website www.orexigen.com
   Google Scholar
• Arena Pharm website http://wwwials.arenapharm.com/wt/page/lho.html
   Google Scholar
• Tschop M Smiley DL Heiman ML Ghrelin induces adiposity in rodents Nature 2000 407 6806 908 913 11057670
   PubMed Web of Science ®Google Scholar
• Wren AM Small CJ Abbott CR Ghrelin causes hyperphagia and obesity in rats Diabetes 2001 50 11 2540 2547 11679432
   PubMed Web of Science ®Google Scholar
• Cummings DE Weigle DS Frayo RS Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery N Engl J Med 2002 346 21 1623 1630 12023994
   PubMed Web of Science ®Google Scholar
• Cummings DE Clement K Purnell JQ Elevated plasma ghrelin levels in Prader Willi syndrome Nat Med 2002 8 7 643 644 12091883
   PubMed Web of Science ®Google Scholar
• Zigman JM Elmquist JK In search of an effective obesity treatment: a shot in the dark or a shot in the arm? Proc Natl Acad Sci U S A 2006 103 35 12961 12962 16924097
   PubMed Web of Science ®Google Scholar
• Farooqi IS Matarese G Lord GM Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency J Clin Invest 2002 110 8 1093 1103 12393845
   PubMed Web of Science ®Google Scholar
• Heymsfield SB Greenberg AS Fujioka K Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial JAMA 1999 282 16 1568 1575 10546697
   PubMed Web of Science ®Google Scholar
• Zelissen PM Stenlof K Lean ME Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial Diabetes Obes Metab 2005 7 6 755 761 16219020
   PubMed Web of Science ®Google Scholar
• Hukshorn CJ Westerterp-Plantenga MS Saris WH Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severely energy-restricted, overweight men Am J Clin Nutr 2003 77 4 771 776 12663271
   PubMed Web of Science ®Google Scholar
• Rosenbaum M Goldsmith R Bloomfield D Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight J Clin Invest 2005 115 12 3579 3586 16322796
   PubMed Web of Science ®Google Scholar
• Oral EA Simha V Ruiz E Leptin-replacement therapy for lipodystrophy N Engl J Med 2002 346 8 570 578 11856796
   PubMed Web of Science ®Google Scholar
• Batterham RL Cowley MA Small CJ Gut hormone PYY(3–36) physiologically inhibits food intake Nature 2002 418 6898 650 654 12167864
   PubMed Web of Science ®Google Scholar
• Batterham RL Cohen MA Ellis SM Inhibition of food intake in obese subjects by peptide YY3–36 N Engl J Med 2003 349 10 941 948 12954742
   PubMed Web of Science ®Google Scholar
• Gantz I Erondu N Mallick M Efficacy and safety of intranasal peptide YY3–36 for weight reduction in obese adults J Clin Endocrinol Metab 2007 92 5 1754 1757 17341568
   PubMed Web of Science ®Google Scholar
• Wynne K Park AJ Small CJ Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial Diabetes 2005 54 8 2390 2395 16046306
   PubMed Web of Science ®Google Scholar
• Barsh GS Farooqi IS O’Rahilly S Genetics of body-weight regulation Nature 2000 404 6778 644 651 10766251
   PubMed Web of Science ®Google Scholar
• Huszar D Lynch CA Fairchild-Huntress V Targeted disruption of the melanocortin-4 receptor results in obesity in mice Cell 1997 88 1 131 141 9019399
   PubMed Web of Science ®Google Scholar
• Butler AA Marks DL Fan W Kuhn CM Bartolome M Cone RD Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat Nat Neurosci 2001 4 6 605 611 11369941
   PubMed Web of Science ®Google Scholar
• Xiang Z Pogozheva ID Sorenson NB Peptide and small molecules rescue the functional activity and agonist potency of dysfunctional human melanocortin-4 receptor polymorphisms Biochemistry 2007 46 28 8273 8287 17590021
   PubMed Web of Science ®Google Scholar
• Madison LD Marks DL Anticatabolic properties of melanocortin-4 receptor antagonists Curr Opin Clin Nutr Metab Care 2006 9 3 196 200 16607116
   PubMed Web of Science ®Google Scholar
• Cai M Mayorov AV Ying J Design of novel melanotropin agonists and antagonists with high potency and selectivity for human melanocortin receptors Peptides 2005 26 8 1481 1485 15876475
   PubMed Web of Science ®Google Scholar
• Bray GA Greenway FL Pharmacological treatment of the overweight patient Pharmacol Rev 2007 59 2 151 184 17540905
   PubMed Web of Science ®Google Scholar